{"id":101688,"date":"2025-05-14T20:23:45","date_gmt":"2025-05-14T20:23:45","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/101688\/"},"modified":"2025-05-14T20:23:45","modified_gmt":"2025-05-14T20:23:45","slug":"ex-revolut-and-nhs-team-launches-emerald-with-625k-to-unite-health-data-into-one-ai-powered-preventive-plan-tfn","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/101688\/","title":{"rendered":"Ex-Revolut and NHS team launches Emerald with \u00a3625K to unite health data into one AI-powered preventive plan \u2014 TFN"},"content":{"rendered":"

The UK faces a significant health crisis: 65% of preventable deaths are attributable<\/a> to avoidable causes. Despite this, 37% of cancer cases are detected<\/a> only when patients arrive at A&E. Moreover, more than a quarter of UK millennials feel<\/a> dismissed when voicing health concerns to medical professionals. This highlights a broader systemic issue: while the NHS excels at acute care, it isn\u2019t structured to deliver proactive, personalised preventive health at scale.<\/p>\n

Emerald, a preventive health platform combining diagnostics, AI, and continuous GP access, aims to address a critical gap in healthcare: the lack of adequate preventive care for healthy individuals who want to take proactive steps. Globally, preventive health is booming, with the market projected to reach<\/a> $773 billion by 2034, as stakeholders recognise the benefits of early intervention.<\/p>\n

Speaking exclusively to TFN, Alexander Badalyan<\/a>, co-founder and CEO of Emerald, shared: \u201cWhat we\u2019re seeing is a generation that\u2019s highly engaged with their health \u2013 tracking sleep, stress, exercise, nutrition \u2013 but they\u2019re doing it in silos. Everyone\u2019s tracking something, but no one is helping them connect the dots. The NHS isn\u2019t designed to support proactive optimisation. Doctors don\u2019t have the time, and private options are either fragmented or unaffordable.\u201d<\/p>\n

Badalyan added, \u201cEmerald brings it all together. We combine comprehensive biomarker testing, longitudinal health tracking, wearables integration, and GP-led insight to give people a full picture of their health, and a plan to stay ahead of illness.\u201d\u00a0<\/p>\n

Today, the company emerged from stealth with \u00a3625,000 in funding from prominent European founders, operators, and professional athletes. Notable contributors include Mart Abramov (ex-Wise and founder of TaxScouts), Mike Benchimol (ex-Checkout.com and COO of H Company<\/a>), Jane Austin (ex-Babylon Health), Patrick Bamford, Harry Glorikian (Scientia Ventures), Nikolay Tretiakov (Leafy Tunnel<\/a>), and Johann Huber (founder of Soma Analytics), alongside several General Partners from top VC firms investing personally. This diverse backing reflects growing confidence in digital health, with UK healthtech investment reaching \u00a33.8 billion in 2023.<\/p>\n

How Emerald helps people take control of their health before symptoms emerge<\/p>\n

Emerald is a UK-based healthtech company reimagining preventive care. Combining diagnostics, AI, and GP insights helps people take control of their health before symptoms appear. The platform\u2019s AI engine analyses data from blood tests, wearables, and lifestyle inputs, identifying early warning signs and suggesting actionable steps\u00a0 \u2014an integrated approach rarely found in existing NHS and private pathways.<\/p>\n

Emerald\u2019s founding team balances medical and fintech expertise. CEO Badalyan previously cofounded Mashroom (a UK proptech\/insurtech startup), CTO Anton Shchipanov<\/a> developed software at Revolut, and Head of AI Nazar Beknazarov<\/a> trained LLMs at Toloka<\/a>, a GenAI provider. Dr McNally leads the clinical side, bringing experience from publishing London\u2019s first 28-day COVID mortality study and advising healthtech companies at Oliver Wyman. This combination uniquely positions Emerald to bridge cutting-edge technology and robust clinical governance.<\/p>\n

Co-founders Alexander Badalyan and Anton Shchipanov initially planned to build a premium credit card platform \u2014 a UK challenger to Amex, Yonder, and similar services. However, early user interviews revealed an unexpected insight.<\/p>\n

\u201cWe asked people what they\u2019d include in their dream Amex membership benefits. So many mentioned prevention perks \u2013 annual health screens, GP access, health tracking,\u201d said Badalyan. \u201cWe first thought we\u2019d build something like a credit card with wellness benefits. But we quickly realised people weren\u2019t asking for perks \u2013 they were voicing unmet needs around their health.\u201d<\/p>\n

This revelation led the team to pivot entirely to healthtech and bring on their third co-founder, Dr Dan McNally, to lead Emerald\u2019s clinical strategy and operations. Such pivots are increasingly common in the UK\u2019s dynamic startup scene, where founders follow genuine user pain points, especially in high-stakes sectors like healthcare.<\/p>\n

In its invite-only Alpha, Emerald has already identified early signs of cardiovascular risks, thyroid issues, and metabolic conditions, enabling users to act before symptoms develop. Its GP team provides guidance, action points, and referrals as needed.<\/p>\n

Emerald aims to transform preventive health by helping people track, understand, and act on their health before illness strikes. Unlike full-stack providers such as Sweden\u2019s Neko Health, which operates its clinics, Emerald partners with hundreds of UK diagnostic centres. Users can receive a comprehensive 10-minute screening covering blood, urine, and physical metrics, then get personalised health plans based on their data, with GP oversight.<\/p>\n

\u201cEveryone\u2019s tracking something, but no one\u2019s tying it together. Doctors don\u2019t have time, and the NHS won\u2019t do it for people who aren\u2019t sick. But people are starving for insight that could prevent illness,\u201d said Alexander Badalyan, co-founder and CEO. \u201cThink of Emerald as your doctor-led preventive health companion, powered by data and AI.\u201d<\/p>\n

Becoming the default platform for proactive health management<\/p>\n

Badalyan concluded: \u201cOver the next 3\u20135 years, we\u2019ll scale rapidly across the UK, building evidence for integration with private insurers and the NHS. Our asset-light model, partnering with existing clinics rather than operating them, enables quick expansion into new markets. We\u2019ve already explored several international regions where preventive care infrastructure is lacking, but demand is growing.\u201d<\/p>\n

He added: \u201cOur long-term vision is to become the default platform for proactive health management \u2014 globally accessible, medically grounded, and centred on the individual rather than the illness.\u201d<\/p>\n

With thousands on Emerald\u2019s waitlist and Beta launching to the public, the company is gradually expanding access while calibrating GP availability. Early users include Team GB athletes, clinicians, and multiple VCs who joined the waitlist to try the product.<\/p>\n

Emerald\u2019s 12-month membership includes two in-person screenings covering more than 115 biomarkers, full access to an AI-powered health dashboard, one-to-one GP chat support for preventive health queries and referrals, wearable and past lab integration, and dynamic goals with ongoing recommendations.<\/p>\n

\u201cMost online services focus on a single issue \u2014 diabetes, skin, fertility \u2014 leaving users to piece together the rest,\u201d said Dr. McNally. \u201cWe start with the complete picture and guide users from there.\u201d As digital health matures, platforms like Emerald, offering holistic, integrated care, are poised to become the gold standard, helping millions live healthier, longer lives.<\/p>\n","protected":false},"excerpt":{"rendered":"The UK faces a significant health crisis: 65% of preventable deaths are attributable to avoidable causes. Despite this,…\n","protected":false},"author":2,"featured_media":101689,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[323,105,4348,22983,257,12,3322,16,15],"class_list":{"0":"post-101688","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-ai","9":"tag-health","10":"tag-healthcare","11":"tag-healthtech","12":"tag-london","13":"tag-news","14":"tag-startups","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114508062057732784","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/101688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=101688"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/101688\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/101689"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=101688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=101688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=101688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}